Document is current
Any future updates will be listed below
-
Authors
Molina-Alejandre, Marta
Perea, Francisco
Calvo, Virginia
Martinez-Toledo, Cristina
Nadal, Ernest https://orcid.org/0000-0002-9674-5554
Sierra-Rodero, Belén
Casarrubios, Marta
Casal-Rubio, Joaquín
Martinez-Martí, Alex
Insa, Amelia
Massuti, Bartomeu
Viteri, Santiago
Barneto Aranda, Isidoro
Rodriguez-Abreu, Delvys
de Castro, Javier
Martínez, Joaquín Mosquera
Cobo, Manuel
Wistuba, Ignacio I
Parra, Edwin R
Martín-López, Javier https://orcid.org/0000-0001-6361-3689
Megías, Diego
Muñoz-Viana, Rafael
Garrido, Federico
Aptsiauri, Natalia https://orcid.org/0000-0001-8419-2959
Ruiz-Cabello, Francisco
Provencio, Mariano
Cruz-Bermúdez, Alberto https://orcid.org/0000-0001-5136-7011
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03081689 at ClinicalTrials.govnct03081689 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
https://doi.org/10.1136/jitc-2022-005320
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009762
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
https://doi.org/10.1136/jitc-2021-002804
734 Tertiary lymphoid structures as hallmarks of response to neoadjuvant chemoimmunotherapy in locally advanced non-small cell lung cancer NADIM trial
https://doi.org/10.1136/jitc-2025-sitc2025.0734
nct03081689 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
https://doi.org/10.1136/jitc-2022-005320
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009762
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
https://doi.org/10.1136/jitc-2021-002804
734 Tertiary lymphoid structures as hallmarks of response to neoadjuvant chemoimmunotherapy in locally advanced non-small cell lung cancer NADIM trial
https://doi.org/10.1136/jitc-2025-sitc2025.0734
Documents that mention this clinical trial
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
https://doi.org/10.1136/jitc-2022-005320
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009762
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
https://doi.org/10.1136/jitc-2021-002804
734 Tertiary lymphoid structures as hallmarks of response to neoadjuvant chemoimmunotherapy in locally advanced non-small cell lung cancer NADIM trial
https://doi.org/10.1136/jitc-2025-sitc2025.0734
-
Funding
Funding for this research was provided by:
Asociación Española Contra el Cáncer (Ayuda Predoctoral Madrid 2023)
European Union’s Horizon 2020 research and innovation programme (CLARIFY 875160)
Comunidad de Madrid (PIPF-2022/SAL-GL-25283)
Andalusian Government (B-CTS-410-UGR-20)
Andalusian Government (Group CTS-143)
BMS (NADIM Clinical Trial)
European Regional Development Fund (PI19/01652)
European Regional Development Fund (PI22/01223)
Ministry of Science and Innovation (CPP2022-009545 'STRAGEN-IO')
Ministry of Science and Innovation (PID2020-115087GB-100)
Ministry of Science and Innovation (RTC2017-6502-1 'INmunoSIGHT')
Ministry of Science and Innovation (RTC2019-007359-1 'BLI-O')
Instituto de Salud Carlos III (CP23/00044)
Instituto de Salud Carlos III (PI19/01652)
Instituto de Salud Carlos III (PI22/01223)
Instituto de Salud Carlos III (PI23/01054)
FEDER (B-CTS-410-UGR-20)
FEDER (Group CTS-143)
ThermoFisher (TCR sequencing)
- License Information
